30 July 2013

US court rules Teva patent invalid

A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.

In a ruling at the US Court of Appeals for the Federal Circuit on Friday, July 26, Teva Pharmaceuticals was told one of its patents protecting the Copaxone drug was invalid. The patent in question was due to expire in 2015; other patents at issue were upheld by the court, but these expire in 2014.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation & Industry

UK unveils £1bn sector investment push after recent setbacks

30 October 2026 With its goal of becoming a global life sciences leader still some way off, the UK is betting on new investment, AI and regulatory changes to help close the gap, according to the government’s autumn budget.

Careers

Justice Joanna Smith appointed to interim High Court role as Sir Colin Birss replaces Sir Geoffrey Vos

30 October 2026 Mrs Justice Joanna Smith becomes deputy president of the Business and Property Division of the UK High Court, as Sir Colin Birss fills Sir Geoffrey Vos’ shoes as master of the rolls upon his retirement.

MedTech

Oura targets Ultrahuman’s redesigned smart ring following import ban

29 October 2026 The Finnish wearable tech company strikes again after the Indian rival’s redesigned ring cleared US Customs, with one of Oura’s asserted patents issued just two days earlier.